N-[[(5S)-3-[3-fluoro-4-(2-piperidin-4-ylethoxy)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide | 1066557-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-[[(5S)-3-[3-fluoro-4-(2-piperidin-4-ylethoxy)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 1066557-25-2
• 化学式: C₁₉H₂₆FN₃O₄
• 分子量: 379.432
• InChiKey: UOPYPAQPTUCAPU-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  环丙基萘啶羧酸 、 N-[[(5S)-3-[3-fluoro-4-(2-piperidin-4-ylethoxy)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 在 三甲基氯硅烷 、 TEA 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成
  参考文献：
  名称：

  Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action

  摘要：

  Oxazolidinone-quinolone hybrids, which combine the pharmacophores of a quinolone and an oxazolidinone, were synthesised and shown to be active against a variety of susceptible and resistant Gram-positive and Gram-negative bacteria. The nature of the spacer greatly influences the antibacterial activity by directing the mode of action, that is quinotone- and/or oxazolidinone-like activity. The best compounds in this series have a balanced dual mode of action and overcome all types of resistance, including resistance to quinolones and linezolid, in clinically relevant Gram-positive pathogens. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.028
• 作为产物：
  描述：

  3,4-二氟硝基苯 在 palladium on activated charcoal 盐酸 、 正丁基锂 、 sodium azide 、 TEA 、 水 、 氢气 、 sodium hydride 、 碳酸氢钠 、 溶剂黄146 、 三苯基膦 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 N-[[(5S)-3-[3-fluoro-4-(2-piperidin-4-ylethoxy)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
  参考文献：
  名称：

  Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action

  摘要：

  Oxazolidinone-quinolone hybrids, which combine the pharmacophores of a quinolone and an oxazolidinone, were synthesised and shown to be active against a variety of susceptible and resistant Gram-positive and Gram-negative bacteria. The nature of the spacer greatly influences the antibacterial activity by directing the mode of action, that is quinotone- and/or oxazolidinone-like activity. The best compounds in this series have a balanced dual mode of action and overcome all types of resistance, including resistance to quinolones and linezolid, in clinically relevant Gram-positive pathogens. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.028

文献信息

• Intermediate products for producing oxazolidinone-quinolone hybrids
  申请人：Hubschwerlen Christian

  公开号：US20070004769A1

  公开（公告）日：2007-01-04

  The present invention describes intermediates (ZP) for a novel and efficient synthesis of compounds in which the pharmacophores of quinolone and oxazolidinone are linked to one another by way of a chemically stable linker.

  本发明描述了一种中间体（ZP），用于一种新颖有效的化合物合成方法，其中喹诺酮和噁唑烷酮的药效团通过化学稳定的连接剂相互连接。
• ZWISCHENPRODUKTE FÜR DIE HERSTELLUNG VON OXAZOLIDINON-CHINOLON HYBRIDEN
  申请人：Morphochem Aktiengesellschaft Für Kombinatorische Chemie

  公开号：EP1660489B1

  公开（公告）日：2014-07-02
• US7557214B2
  申请人：——

  公开号：US7557214B2

  公开（公告）日：2009-07-07
• US8124772B2
  申请人：——

  公开号：US8124772B2

  公开（公告）日：2012-02-28
• Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action
  作者：Christian Hubschwerlen、Jean-Luc Specklin、Daniel K. Baeschlin、Yves Borer、Sascha Haefeli、Christine Sigwalt、Susanne Schroeder、Hans H. Locher

  DOI：10.1016/j.bmcl.2003.07.028

  日期：2003.12

  Oxazolidinone-quinolone hybrids, which combine the pharmacophores of a quinolone and an oxazolidinone, were synthesised and shown to be active against a variety of susceptible and resistant Gram-positive and Gram-negative bacteria. The nature of the spacer greatly influences the antibacterial activity by directing the mode of action, that is quinotone- and/or oxazolidinone-like activity. The best compounds in this series have a balanced dual mode of action and overcome all types of resistance, including resistance to quinolones and linezolid, in clinically relevant Gram-positive pathogens. (C) 2003 Elsevier Ltd. All rights reserved.